Cannabinoid Derived Pharmaceuticals Summit Europe

2019 was a ground breaking year for cannabinoid derived pharmaceuticals in Europe, with growing interest in European research into their therapeutic potential. December 2019 saw the successful fast-track approval of a cannabinoid-based epilepsy drug into the UK’s NHS.

This focused conference will put you in front of the research teams exploring the future of therapeutic cannabinoids in a host of disease areas for patients with unmet clinical needs. The comprehensive agenda will address the end to end development challenges which are holding back clinical and commercial success, and give you the insight from world-leading experts to overcome the most critical hurdles.

With 20+ hours of content, interactive workshops and 5 hours+ of networking with your fellow drug developers, this is the only European conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications.

Join us and leading experts from Cannabics, CannRx, Emerald Biosciences, InMed Pharmaceuticals and more to discuss target biology, compound formulation, safety testing, patient engagement, trial design and commercialisation.

Early booking and group discounts apply. Academic rates also available - see the website for details.

Speakers: Simon Benita, Professor and Chairman, Hebrew University of Jerusalem and BioNanoSim Ltd, Eyal Ballan, CTO, Cannabics Pharma, Shimon Lecht, Chief of R&D, CannnRx, Clifton Flack, CEO and Co-Founder, CiiTECH, Brian Murphy, CEO, Emerald Bioscience, Manuel Alfaro De Pra, R&D Coordinator, Entourage Phytolab, Mikael Sodergren, Senior Clinical Lecturer, Imperial College London, Karen Long, Director of Drug Development, InMed Pharmaceuticals, Michael Woudenberg, VP Chemistry Manufacturing and Control, InMed Pharmaceuticals, Jahan Marcu, CSO, International Research Center on Cannabis and Health, Deepak Anand, CEO and Co-Founder, Materia Ventures, Ron Lipsky, Vice President, Business Development and International Relations, MGC Pharmaceuticals, Ltd., Alexandros Makriyannis, Director, Center for Drug Discovery, Northeastern University, Saeid Babaei, CEO, Orpheus Medica, Andrea Leone-Bay, CSO, Receptor Life Sciences, Arnold Lippa, CEO and Co-Founder, RespireRx Pharmaceuticals, Jeff Margolis, CFO, RespireRx Pharmaceuticals, Zohar Koren, CEO, SciCann Therapeutics, Aurelia De Pauw, Vice-President Clinical Programs/ Medical Affairs, Tetra Bio-Pharma, Pavel Gershkovich, Associate Professor of Biopharmaceutics, University of Nottingham, Cris Constantinescu, Professor of Neurology, University of Nottingham, Mauro Maccarrone, Professor and Chair of Biochemistry and Molecular Biology, University of Rome

Others Details

Time: 9:00 am to 5:00 pm URL: Brochure: https://go.evvnt.com/584421-3?pid=6581